14 results about "Multilayer tablet" patented technology

A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, nicotine, and at least one sugar alcohol, and wherein the second layer comprises at least one sugar alcohol.

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

A process is disclosed for the manufacture of a compressed product consisting of a multilayer tablet formed in a single compression operation.

Dosage form, in particular dietary supplement and / or pharmaceutical dosage form, especially for oral administration, preferably for promoting and / or supporting, in particular for non-therapeutic and / or non-medical promotion and / or support, preferably for preventive and / or curative promotion and / or support, sleep health and / or sleep behavior, in particular sleep onset and / or maintenance, and / or preferably for use in the prophylactic and / or therapeutic medical treatment of sleep disorders, in particular sleep onset and / or maintenance, and / or dysregulation of the natural day / night rhythm and / or the circadian rhythm, wherein the dosage form is designed as a multiphase tablet, preferably a multilayer tablet, in particular a two-layer tablet, preferably a three-layer tablet, wherein the dosage form and / or the multiphase tablet has or consists of several, in particular at least two, preferably three, different phases, in particular layers, wherein the different phases, in particular layers, have different disintegration times and / or drug release rates in the gastrointestinal tract, in particular the stomach and / or intestine, after oral administration; where the dosage form and / or the multiphasic tablet is: a) a first phase (“immediate phase”), in particular a first layer (“immediate layer”), with rapid and / or immediate (immediate) disintegration and / or release of the active ingredient in the gastrointestinal tract, in particular the stomach and / or intestine, following oral administration, wherein the first phase, in particular the first layer, (i a ) Melatonin and (ii a ) contains an extract of Ashwagandha (Withania somnifera) (“Ashwagandha extract”), b) a second phase (“depot phase”), in particular a second layer (“depot layer”), with controlled and / or delayed (retarded) disintegration and / or drug release in the gastrointestinal tract, in particular the stomach and / or intestine, following oral administration, wherein the second phase, in particular the second layer, (i b ) Melatonin and (ii b) contains at least one extract of at least one sleep-promoting and / or sedating drug (plant or herb), preferably an extract of valerian (Valeriana officinalis) (“valerian extract”), c) optionally a third phase (“chronophase”), in particular a third layer (“chronolayer”), with continuous disintegration and / or release of the active substance in the gastrointestinal tract, in particular the stomach and / or intestine, following oral administration, wherein the third phase, in particular the third layer, (i c) contains at least one (further) extract of at least one sleep-promoting and / or sedating drug (plant or herb), preferably at least two (further) extracts of different sleep-promoting and / or sedating drugs (plants or herbs), preferably an extract of valerian (Valeriana officinalis) (“valerian extract”) and / or an extract of lavender (Lavandula angustifolia) (“lavender extract”), particularly preferably an extract of valerian (Valeriana officinalis”) (“valerian extract”) and an extract of lavender (Lavandula angustifolia) (“lavender extract”); in particular wherein the dosage form contains melatonin in a total amount of at least 1.5 mg, in particular in a total amount in the range of 1.5 mg to 5 mg; and / or in particular wherein the dosage form contains withanolide glycosides, in particular withanolide glycosides provided by the extract of Ashwagandha, in a total amount of at least 10 mg, in particular in a total amount in the range of 10 mg to 500 mg.

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, nicotine, and at least one sugar alcohol, and wherein the second layer comprises at least one sugar alcohol.

A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, and wherein the second layer comprises at least one sugar alcohol and nicotine.

A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

The invention discloses an anti-uterine cancer traditional Chinese medicine targeted multilayer tablet and a preparation method thereof, and is characterized in that the anti-uterine cancer traditional Chinese medicine targeted multilayer tablet is prepared from the following components by weight: 150-250g of edible tulip, 75-90g of toad skin, 150-200g of centipede, 80-120g of astragalus membranaceus, 100-150g of fructus viticis, 50-80g of ganoderma lucidum spore powder, 50-60g of sculellaria barbata, 100-150g of semen coicis, 20-40g of liquorice and 60-100g of oldenlandia diffusa. The medicine effect can be improved, and growth, metastasis and diffusion of tumors can be effectively inhibited.

The present invention relates to pharmaceutical compositions in multi-layer tablet form comprising dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as active substances.

A soluble oral adhesive tablet for sustained release is disclosed, the tablet comprising an active ingredient wherein the tablet is a multi-layer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.

A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.

A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, and wherein the second layer comprises at least one sugar alcohol and nicotine.